Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Trial Profile

An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neratinib (Primary) ; Fulvestrant; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer; Biliary cancer; Bladder cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Glioblastoma; Glioma; Gliosarcoma; Liver cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Salivary gland cancer; Solid tumours; Uterine cancer
  • Focus Therapeutic Use
  • Acronyms SUMMIT
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 06 Nov 2019 According to a Puma Biotechnology media release, the company plans to report data from this study in the fourth quarter of 2019.
    • 23 Sep 2019 Results assessing PET Response Criteria in identification of patients eligible for trial accrual published in the Clinical Cancer Research.
    • 08 Aug 2019 According to a Puma Biotechnology media release, company is anticipating a meeting with the FDA to discuss the clinical development and regulatory strategy for this trial in the third quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top